HomepageSNPHF • OTCMKTS
add
Santen Pharmaceutical Co Ltd
Vorige slotkoers
$ 10,53
Jaar-range
$ 9,26 - $ 12,46
Beurswaarde
487,08 mld. JPY
Koers/winst
-
Dividendrendement
-
Primaire beurs
TYO
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (JPY) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 76,37 mld. | -0,85% |
Bedrijfskosten | 30,91 mld. | -8,61% |
Netto inkomsten | 8,69 mld. | 18,56% |
Netto winstmarge | 11,38 | 19,54% |
Winst per aandeel | — | — |
EBITDA | 15,83 mld. | 0,55% |
Effectief belastingtarief | 24,64% | — |
Balans
Totale activa
Totale passiva
| (JPY) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 77,85 mld. | -5,09% |
Totale activa | 398,31 mld. | -6,90% |
Totale passiva | 115,10 mld. | -11,35% |
Totaal aandelenvermogen | 283,21 mld. | — |
Uitstaande aandelen | 341,35 mln. | — |
Koers-boekwaardeverhouding | 0,01 | — |
Rendement op activa | 7,01% | — |
Rendement op kapitaal | 9,91% | — |
Kasstroom
Nettomutatie in liquide middelen
| (JPY) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 8,69 mld. | 18,56% |
Operationele kasstroom | 13,73 mld. | -56,70% |
Kasstroom uit beleggingen | -2,77 mld. | -42,37% |
Kasstroom uit financiering | -20,22 mld. | -73,43% |
Nettomutatie in liquide middelen | -6,59 mld. | -138,09% |
Vrije kasstroom | 9,01 mld. | -68,47% |
Over
Santen Pharmaceutical Co., Ltd., is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries.
The company was founded in 1890 by Kenkichi Taguchi, as Taguchi Santendo, and in 1925, Santendo Co., Ltd. was established. In 2014 Santen announced that it has entered into an agreement with Merck & Co. to purchase Merck's ophthalmology products. Wikipedia
Opgericht
1890
Hoofdvestiging
Website
Werknemers
3.744
